Altered pharmacokinetics of a novel anticancer drug, UCN-01, caused by specific high affinity binding to α1-acid glycoprotein in humans

Cancer Research

Volumn 59, Issue 5, 1999, Pages 1054-1060

  Fuse, Eiichi ^a   Tanii, Hiromi ^a   Takai, Katsumi ^a   Asanome, Kazuki ^a   Kurata, Noriaki ^a   Kobayashi, Hiroyuki ^a   Kuwabara, Takashi ^a   Kobayashi, Satoshi ^a   Sugiyama, Yuichi ^b  

^a KYOWA HAKKO KOGYO CO LTD   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

7 HYDROXYSTAUROSPORINE; OROSOMUCOID;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CELL CYCLE G1 PHASE; CELL PROLIFERATION; DRUG EFFECT; GROWTH INHIBITION; HUMAN; HUMAN CELL; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; RECEPTOR AFFINITY; TUMOR GROWTH;

ALKALOIDS; ANIMALS; ANTINEOPLASTIC AGENTS; CELLS, CULTURED; DOGS; HAPLORHINI; HUMANS; INJECTIONS, INTRAVENOUS; LIVER; MALE; METABOLIC CLEARANCE RATE; MICE; MICE, INBRED STRAINS; OROSOMUCOID; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; SERUM ALBUMIN; SPECIES SPECIFICITY; STAUROSPORINE;

EID: 0033104319     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Akinaga, S., Gomi, K., Morimoto, M., Tamaoki, T., and Okabe, M. Antitumor activity of UCN-01, a selective inhibitor of protein kinase C, in murine and human tumors models. Cancer Res., 51: 4888-4892, 1991.
2. Akinaga, S., Nomura, K., Gomi, K., and Okabe, M. Enhancement of antitumor activity of mitomycin C in vitro and in vivo by UCN-01, a selective inhibitor of protein kinase C. Cancer Chemother. Pharmacol., 32: 183-189, 1993.
3. Seynaeve, C. M., Steller-Stevenson, M., Sebers, S., Kaur, G., Sausville, E. A., and Worland, P. J. Cell cycle arrest and inhibition by the protein kinase antagonist UCN-01 in human breast carcinoma cells. Cancer Res., 53: 2081-2086, 1993.
4. Takahashi, I., Kobayashi, E., Asano, K., Yoshida, M., and Nakano, H. UCN-01, a selective inhibitor of protein kinase C from Streptomyces. J. Antibiot., 40: 1782-1784, 1987.
5. Kawakami, K., Futami, H., Takahara, J., and Yamaguchi, K. UCN-01, 7-hydroxyl-staurosporine, inhibits kinase activity of cyclin-dependent kinase and reduces the phosphorylation of the retinoblastoma susceptibility gene product in an A549 human lung carcinoma cell line. Biochem. Biophys. Res. Commun., 219: 778-783, 1996.
6. 1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as induction of CDK inhibitor p21/Cipl/WAFI/Sdil in p53-mutated human epidermoid carcinoma A431 cells. Cancer Res., 57: 1495-1501, 1997.
7. Pollack, I. F., Kawecki, S., and Lazo, J. S. Blocking of glioma proliferation in vitro and in vivo and potentiating the effects of BCNU and cisplatin: UCN-01, a selective protein kinase inhibitor. J. Neurosurg., 84: 1024-1032, 1996.
8. Bunch, R. T. and Eastman, A. Enhancement of cisplatin-induced cytotoxicity by 7-hydroxystaurosporine (UCN-01), a new G2-checkpoint inhibitor. Clin. Cancer Res., 2: 791-797, 1996.
9. 1-acid glycoprotein. Cancer Res., 58: 3248-3253, 1998.
10. 1-acid glycoprotein. Proceedings of the 10th NCI-EORTC symposium on new drugs in cancer therapy. Annals of Oncology, Suppl 2. in press.
11. Wagner, J. G. Protein binding. In: J. G. Wagner (ed.), Pharmacokinetics for the Pharmaceutical Scientist. pp. 243-258. Lancaster: Technomic Publishing, 1993.
12. Wilkinson, G. R. Plasma and tissue binding considerations in drug disposition. Drug Metab. Rev., 14: 427-465, 1983.
13. Kremer, J. M. H., Willing, J., and Janssen, L. H. M. Drug binding to human alpha-1-acid glycoprotein in health and disease. Pharmacol. Rev., 40: 1-47, 1988.
14. Holladay, J. W., Dewey, M. J., and Yoo, S. D. Steady-state kinetics of imipramine in transgenic mice with elevated serum AAG levels. Pharm. Res. (NY), 13: 1313-1316, 1996.
15. Yoo, S. D., Holladay, J. W., Fincher, T. K., Baumann, H., and Dewey, M. J. Altered disposition and antidepressant activity of imipramine in transgenic mice with elevated alpha-1-acid glycoprotein. J. Pharmacol. Exp. Ther., 276: 918-922, 1996.
16. Yasuhara, M., Fujiwara, J., Kitade, S., Katayama, H., Okumura, K., and Hori, R. Effect of altered plasma protein binding on pharmacokinetics and pharmaco-dynamics of propranolol in rats after surgery: role of alpha-1-acid glycoprotein. J. Pharmacol. Exp. Ther., 235: 513-520, 1985.
17. Yuan, J., Yang, D. C., Birkmeier, J., and Stolzenbach, J. Determination of protein binding by in vitro charcoal adsorption. J. Pharmacokinet. Biopharm., 23: 41-55, 1995.
18. Sablonnière, B., Dallery, N., Grillier, I., Formstecher, P., and Dautrevaux, M. Physicochemical parameters affecting the charcoal adsorption assay for quantitative retinoid-binding measurement. Anal. Biochem., 217: 110-118, 1994.
19. Kurata, N., Kuwabara, T., Tanii, H., Fuse, E., Akiyama, T., Akinaga, S., Kobayashi, H., Yamaguchi, K., and Kobayashi, S. Pharmacokinetics and pharmacodynamics of a novel protein kinase inhibitor, UCN-01, Cancer Chemother. Pharmacol., in press, 1999.
20. Seglen, P. O. Preparation of rat liver cells. III. Enzymatic requirement for tissue dispersion. Exp. Cell Res., 82: 391-398, 1973.
21. +-independent multispecific anion transporter mediates active transport of pravastatin into rat liver. Am. J. Physiol., 264: G36-G44, 1993.
22. Kurata, N., Kuramitsu, T., Tanii, H., Fuse, E., Kuwabara, T., Kobayashi, H., and Kobayashi, S. Development of a highly sensitive high-performance liquid chromatographic method for measuring an anticancer drug, UCN-01 in human plasma or urine. J. Chromatogr. B. 708: 223-227, 1998.
23. Gibaldi, M., and Perrier, D. Noncompartment analysis based on statistical moment theory. In: M. Gibaldi and D. Perrier (eds.), Pharmacokinetics, pp. 409-417. New York: Marcel Dekker, 1982.
24. Davies, B., and Morris, T. Physiological parameters in laboratory animals and humans, Pharm. Res., 10: 1093-1095, 1993.
25. Hassen, A. M., Lam, D., Chiba, M., Tan, E., Geng, W., and Pang, K. S. Uptake of sulfate conjugates by isolated rat hepatocytes. Drug Metab. Dispos., 24: 792-797, 1996.
26. 1-acid glycoprotein infusion in the rat. J. Pharm. Sci., 76: 101-104, 1987.
27. 1-acid glycoprotein after induction of the acute phase response in rats. J. Pharm. Pharmacol., 44: 447-450, 1992.
28. 1-acid glycoprotein. Clin. Pharmacokinet., 11: 336-342, 1986.
29. Weisman, S., Goldsmith, B., Winzler, R., and Lepper, M. H. Turnover of plasma orosomucoid in man. J Lab. Clin. Med., 57: 7-15, 1961.
30. Hervé. F., Duché, J., d'Athis, P., Marché, C., Barré, J., and Tillement, J. Binding of disopyramide, methadone, dipyridamole, chlorpromazine, lignocaine and progesterone to the two main genetic variants of human alpha-1-acid glycoprotein: evidence for drug-binding differences between the variants and for the presence of two separate drug-binding sites on alpha-1-acid glycoprotein. Pharmacogenetics, 6: 403-415, 1996.
31. Fuse, E., Kobayashi, T., Inaba, M., and Sugiyama, Y. Prediction of the maximal tolerated dose (MTD) and therapeutic effect of anticancer drugs in humans: integration of pharmacokinetics with pharmacodynamics and toxicodynamics. Cancer Treat. Rev., 21: 133-157, 1995.